Physician profile
Eloisa Vega
NPI 1427166107
$1,026.73
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $613 · 2020: $97.57 · 2021: $195 · 2022: $122.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $168.75 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2019 | |
| Medtronic Vascular, INC. | $125.00 | 2019 | |
| Vifor Pharma, INC. | $121.70 | 2022 | |
| Sunovion Pharmaceuticals INC. | $97.24 | 2019-2020 | |
| Abbvie INC. | $49.76 | 2021 | |
| Covidien LP | $43.33 | 2019 | |
| Indivior INC. | $38.72 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $33.98 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $29.14 | 2021 | |
| Sanofi Pasteur INC. | $29.14 | 2019-2020 | |
| Novo Nordisk INC | $26.28 | 2021 | |
| Amgen INC. | $24.82 | 2019 | |
| Dynavax Technologies Corporation | $22.15 | 2020 | |
| Neurocrine Biosciences, INC. | $18.88 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $17.81 | 2021 | |
| Supernus Pharmaceuticals, INC. | $15.30 | 2021 | |
| Cranial Technologies, INC | $15.21 | 2019 | |
| Alkermes, INC. | $13.42 | 2021 | |
| Biogen, INC. | $11.10 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eloisa Vega listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.